Viking Therapeutics rises to $41.14 – Analysts see potential up to $101
This article was created with the help of artificial intelligence.
Key Takeaways
- Viking Therapeutics closed on July 9, 2026, at $41.14, a gain of 2.95 percent from the previous day.
- 23 of 24 analysts recommend the stock for purchase, with an average price target of $93.60 (high target: $101).
- The RSI currently stands at 67.73 and is in the neutral to slightly overbought range.
- From the 52-week low of $22.96, the stock has risen 79.2 percent; it is 4.7 percent below the high of $43.15.
- As a clinical-stage biotechnology company, Viking Therapeutics currently generates no revenue, with earnings per share at −$4.15.
- The company initiated a Phase 1 study in June 2026 for the obesity drug candidate VK3019.
Viking Therapeutics Inc. (NASDAQ: VKTX) closed on Wednesday, July 9, 2026, at $41.14, up 2.95 percent from the previous day. Trading volume totaled 1.69 million shares, remaining below the 90-day average of 3.12 million shares.
Price development year-over-year: Up 79 percent from low
In the 52-week comparison, the stock shows resilience: from the annual low of $22.96 (reached in the period July 2025 to July 2026), the price rose 79.2 percent. The stock is currently 4.7 percent below the 52-week high of $43.15. The market capitalization of the California-based biotechnology company stands at $3.44 billion.
Viking Therapeutics is a clinical-stage biotechnology company based in the U.S. specializing in the development of therapies for metabolic and endocrine disorders. The company is in the clinical stage and currently generates no revenue. The earnings per share (EPS) loss was recently −$4.15, and the price-to-book ratio is 6.22.
Technical indicators show neutral picture
The Relative Strength Index (RSI) – a momentum indicator measuring overbought or oversold conditions – stood at 67.73 on July 9, 2026. Values above 70 are considered overbought, below 30 oversold. The current value is in the upper neutral range. In the preceding weeks, the RSI fluctuated between 51.10 (June 18) and 75.36 (June 29), indicating a volatile but overall upward-trending phase.
Analyst consensus: Clear upside potential
24 analysts currently rate the stock (as of July 9, 2026). The distribution shows predominantly positive sentiment:
- Strong Buy: 1 analyst
- Buy: 22 analysts
- Hold: 1 analyst
- Sell / Strong Sell: 0 analysts
The average price target stands at $93.60, representing upside potential of approximately 127 percent from the current price. The median price target is $95. The range spans from a low target of $83 to a high target of $101.
Market environment: Competition in obesity segment intensifies
The obesity and metabolic therapy segment remains highly competitive. Novo Nordisk has gained ground against Eli Lilly with the launch of an oral version of its obesity drug Wegovy. Viking Therapeutics initiated a Phase 1 study in June 2026 for VK3019, a dual amylin/calcitonin receptor agonist for weight reduction, according to company information.
The beta coefficient of Viking stock is 0.64, indicating lower volatility compared to the overall market. A beta below 1 means that the stock has historically fluctuated less than the broader market index.
Risks: No revenue, high development costs
As a clinical-stage company, Viking Therapeutics currently generates no revenue. Development of new drugs is capital-intensive, and the risk of regulatory hurdles and clinical setbacks remains. The negative profit margin and loss per share reflect this stage. For investors in the DACH region, currency risk is an additional consideration, as the stock trades in USD.
The average trading volume of the last 90 days of 3.1 million shares indicates solid liquidity. On July 9, however, volume was significantly lower, which could suggest a wait-and-see stance among market participants.